Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsImmunosenescence and organ transplantationDoes belatacept improve outcomes for kidney transplant recipients? A systematic reviewSirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damageSirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.Late kidney allograft loss: what we know about it, and what we can do about itA prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Sirolimus: its role in nephrology.Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years.Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.The role and value of sirolimus administration in kidney and liver transplantation.The current role of calcineurin inhibitors in posttransplant immunosuppression?Calcineurin inhibitor-free immunosuppression in kidney transplantation.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.Considerations in sirolimus use in the early and late post-transplant periods.Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience.Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant programBiological agents in kidney transplantation: belatacept is entering the field.Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice.Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following TransplantationAn evaluation of sirolimus in renal transplantation.Impact of immunosenescence on transplant outcome.Current pharmacotherapeutical options for the prevention of kidney transplant rejection.Is it time to give up with calcineurin inhibitors in kidney transplantation?Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Immune minimization strategies in renal transplantation.The safety of calcineurin inhibitors for kidney-transplant patients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.Optimising the use of mTOR inhibitors in renal transplantation.N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors.Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
P2860
Q24246340-D1844305-35C4-4AFB-B03E-D4A72D8D692FQ26861735-C0BD71BE-E224-4E82-8822-6F8E1CE331B3Q28084644-876CA63A-60CA-43C8-B3B5-85E2B7F8C511Q31108592-295CE0DE-722A-4CEE-8440-53CA05F18466Q33376348-22105BD4-2B82-4738-985F-94865B8B51D0Q33815032-19EA79F2-4F9A-4AAA-9995-235DCE7B6D5CQ34029931-61F6FFAE-908E-4C8E-BF3C-FD64086665BBQ35153318-B5923D87-9EC8-40F6-8DD2-7CA43EF567F2Q36183858-76C6B261-C8DA-4CE1-BC06-E1FE885F365DQ36341793-FBB5D291-1277-41F8-9BBB-74076C3985A9Q36505718-D325FC55-1377-410F-A0E8-4CDB2C035ABEQ36536752-E0F52840-97AB-4137-A5BF-971194349226Q36652031-6F91FA5D-4365-42FA-93D4-A3A9E39BF9DCQ36733784-7505F6EE-B42D-49AD-B4F5-D7FDEFD412B0Q36889001-50864752-26EE-4281-A881-2AFDDC790C61Q37064446-74A9E09C-91C6-4C22-B6CF-4770209708F4Q37097694-08F0231C-37CF-4DC0-A30C-63FCFDDD41C3Q37517602-AF61145E-6890-4E11-83E6-F6F93E3D0EBFQ37563064-45C5D099-6476-44CB-A177-FFE2587FDCABQ37723175-5C86ADD2-1E63-4D6C-992B-AB67AB9EF139Q37781355-CA2ABA0A-90D1-44F1-AC6A-7662EC4BE1D2Q37859368-54DA625E-A26C-4A8B-BB04-56E894324D3FQ37873950-BBDC72E4-6396-4F94-BEC2-110FD0EA51F9Q37907391-E15F5A1D-5623-4F77-B41D-B81AF19E7F39Q38008362-9D360087-CCE6-4303-B899-0EF346E32593Q38038696-51ECA2ED-C034-41F7-8F7F-DC4648C71A4BQ38063349-C5B45FDF-4D9B-4E4A-AB46-53E37CDFA8D6Q38096463-1DF48076-B37D-4340-A0A6-18E10CD9D6A9Q38156847-CD9AA063-14EA-4CDC-9017-009DAA42557DQ38190678-E838AD0F-1334-4ABE-83DE-C74C2B83C7E6Q38258155-DDEFA970-495B-427F-840A-63F32C571E7AQ38578386-D61972AB-FDC0-49E8-A0D5-B5938DB63EEBQ38668601-F3E5CAFA-BD39-4203-AC65-2C46B0FD7526Q38914374-78F60448-1EA9-45A4-A93C-962C1778EB9CQ41472979-38C1A7DC-9F02-47DE-A332-2A29206046C8Q41928074-E500301E-F304-4496-A8F0-B4FA4427905AQ42010223-C2BAE66C-ECD2-4E76-9ABF-FADBA9BE1005Q42078849-F996C173-C4E5-4584-AE7F-95DC34048A16Q42517229-8D8BE856-898D-42FF-AF66-20675B4D96A0Q42612170-284A0FDF-6B20-4BC8-8697-9E8F52150C03
P2860
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Early cyclosporine withdrawal ...... months after transplantation.
@en
Early cyclosporine withdrawal ...... months after transplantation.
@nl
type
label
Early cyclosporine withdrawal ...... months after transplantation.
@en
Early cyclosporine withdrawal ...... months after transplantation.
@nl
prefLabel
Early cyclosporine withdrawal ...... months after transplantation.
@en
Early cyclosporine withdrawal ...... months after transplantation.
@nl
P2093
P2860
P1476
Early cyclosporine withdrawal ...... months after transplantation.
@en
P2093
Alfredo Mota
Anders Hartmann
Giuseppe Segoloni
Graeme Russ
Henri Kreis
James T Burke
Jeremy Chapman
John F Neylan
Jose R Pinto
Josep M Campistol
P2860
P356
10.1111/J.1432-2277.2004.00052.X
P577
2005-01-01T00:00:00Z